Table 1.
Effects of bath-applied drugs on corticostriatal EPSC baseline amplitude
| Normalized EPSC (baseline | ||
|---|---|---|
| Bath-applied drugs | drugs/baseline control) amplitude | n, Pa |
| d-AP5 (50 μm) | 98 ± 4% | n = 6, P = 0.6076 |
| AM251 (3 μm) | 99 ± 5% | n = 8, P = 0.7988 |
| MCPG (500 μm) | 94 ± 6% | n = 5, P = 0.4029 |
| MPEP (10 μm) | 100 ± 4% | n = 4, P = 0.9243 |
| Pirenzepine (1 μm) | 92 ± 7% | n = 6, P = 0.3739 |
| Nimodipine (1 μm) | 96 ± 4% | n = 4, P = 0.3790 |
| Capsazepine (10 μm) | 100 ± 4% | n = 5, P = 0.9778 |
| AMG9810 (1 μm) | 97 ± 8% | n = 5, P = 0.6800 |
| Picrotoxin (50 μm) | 96 ± 3% | n = 6, P = 0.1493 |
| SCH23390 (4 μm) + sulpiride (10 μm) | 102 ± 2% | n = 7, P = 0.4468 |
a
None of the bath-applied drugs had a significant effect on EPSC baseline amplitude. In all cases, only the baselines with the bath-applied drugs were compared to EPSC baselines measured after 60 min recording.